Recommendations for the treatment of chronic hepatitis B infection in children

Journal of the Pakistan Medical Association

Volumn 57, Issue 4, 2007, Pages 204-207

  Shah, Uzma ^a   Memon, Iqbal ^b   Cheema, Huma Arshad ^c   Ali, Salman ^d   Thobani, Sohail ^e   Mirza, Rashid ^f,g  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^c CHILDREN S HOSPITAL   (Pakistan)

^d Malir National University of Medical Sciences   (Pakistan)

^e BMI Polyclinic   (Pakistan)

^f Mideast Medical Centre   (Pakistan)

^g SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; HEPATITIS A VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; INTERFERON; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; BLOOD TRANSFUSION; BODY FLUID; CHILD; CHRONIC HEPATITIS; ENDEMIC DISEASE; FAMILY HISTORY; FATIGUE; FEVER; HEPATITIS B; HUMAN; LEUKOPENIA; NEEDLESTICK INJURY; PAKISTAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; SCREENING TEST; SEROCONVERSION; SIDE EFFECT; TREATMENT WITHDRAWAL; VERTICAL TRANSMISSION; VIRUS CARRIER; VIRUS DETECTION; VIRUS TRANSMISSION; WEIGHT REDUCTION; BLOOD; FEMALE; MALE; PRESCHOOL CHILD;

ADENINE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; MALE; PAKISTAN; PHOSPHONIC ACIDS; PRACTICE GUIDELINES;

EID: 34249697686     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000;18 (Suppl) 1: S20-2
2. Lee PI, Chang MH, Lee CY, Hsu HY, Chen JS, Chen PJ, et al. Changes in serum HBV DNA and aminotransferase levels during the course of chronic HBV infection in children. Hepatology 1990; 12:657-60.
3. Lok ASK, Lai CL. Acute exacerbations in Chinese patients with chronic HBV infection: Incidence, predisposing factors and etiology. J Hepatol 1990;10:29-34.
4. Lok ASF, McMohan BJ. AASLD practice guidelines for the management of chronic Hepatitis B 200; 39: 857-61.
5. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Eyken PV, et al. Treatment of chronic Hepatitis D with interferon alpha 2a. N Eng J Med 1994;330:88-94.
6. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102:2091-7.
7. Gregorio GV, Jara P, Hierro L, Diaz C, Dela vega A, Lorio R, et al. Lymphoblastoid interferon alpha with or without prednisone pretreatment in children with chronic hepatic B; a multi centre controlled trial. Hepatology 1996; 23:700-7.
8. Lampertico P, Del Ninno E, Manzin A, Donato MF, Romi MG, Iunghi G. et al. A randomized controlled trial of 24 months of interferon alpha 2b in patients with chronic hepatitis B who had HBV DNA withour HbeAg in serum. Hepatology 1997;26:1621-25.
9. Papatheodoridis GV, Manesis E, Hadziyannis SJ. Long term follow up after initial response to interferon alpha therapy in HBeAg negative chronic hepatitis B. Hepatology 2000;32:378a.
10. Jonas MM, Miszerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al. International Pediatric Lamivudine Investigator Group, Clinical trial of Lamivudine in children with chronic Hepatitis B. N Eng J Med 2002; 346: 1706-13.
11. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD mutation during lamivudine therapy. Hepatology 1999;30: 67-72.